• History
• Mission
• Strategy
• Organization
  • Management
  • Board of Directors
  • Scientific Board
• Key Activities

Senior Management

Jens Fogh, DVM

President
Chief Executive Officer
Hillerød, Denmark

is a co-founder of Zymenex A/S and company President and CEO since June 1998.

Prior to co-founding Zymenex A/S, Dr. Fogh was with Novo Nordisk for 15 years, where he held several senior management positions in R&D, International Project Management, Marketing and Quality Assurance. His experience includes Preclinical and Clinical Development, Protein Production, International Marketing and Contract Negotiations as well as International Regulatory Affairs. Dr. Fogh has also served as EFPIA representative and co-author on ICH Guidelines. In his time at Zymenex he has successfully brought projects forward from idea through cloning, process development, proof-of-principle, toxicology and into clinical trials as well as secured Orphan Drug Designation in EU and US.

Dr. Fogh holds a degree in Veterinary Medicine from the Royal Veterinary and Agricultural University, Copenhagen, and has over 50 publications in the fields of cancer, haemophilia and enzyme replacement therapy research.

Team Management

Claes Andersson, PhD

Research Director
Stockholm, Sweden

Dr. Andersson has been employed at Zymenex A/S since 1999, previously as Manager of Biochemistry. Dr. Andersson heads up the Research Team at Lidingö and has been responsible for the development of up- and down stream processes, analytical methods, including scale-up, and transfers to CMO's and CRO's of the company's projects. He has also contributed to the identification of new potential projects. Prior to joining Zymenex, Dr Andersson has held positions as scientist, Project Manager and group- and section Manager at Pharmacia & Upjohn, Sweden, where he was responsible for the development of new analytical methods for some of P&U's recombinant protein projects and also for building up the company's proteomics platform.

Dr. Andersson holds a PhD degree in Biochemistry from Stockholm University and Karolinska Institute, Sweden and is the author of several patents and publications within the field of recombinant proteins.

Pia Ringholm, MSc Pharm

Regulatory and Quality Director
Hillerød, Denmark

Ms. Ringholm is responsible for project planning and managing regulatory and quality assurance systems in Zymenex. She works closely with international authorities and representatives from the pharmaceutical industry as well as international contractors with regards to GMP, GLP and GCP. Ms. Ringholm serves as a Qualified Person. Ms. Ringholm joined Zymenex A/S in 2000 as Manager of Quality Assurance. She has many years of experience from QA, Formulation Development, Quality Control and Aseptic Production in the Pharmaceutical Industry from positions at the State Serum Laboratory from Leo Pharmaceuticals and from Christian Hansen.

Ms. Ringholm holds a Master of Science in Pharmacy from the Royal Danish School of Pharmacy, Copenhagen.